Capsaicin 8% Patch for Peripheral Neuropathic Pain: Review of Treatment Best Practice from ‘Real-World‘ Clinical Experience

• Treede RD , JensenTS, CampbellJN et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70(18) , 1630–1635 (2008).
   PubMed Web of Science ®Google Scholar
• Attal N , CruccuG, BaronRet al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur. J. Neurol. 17(9) , 1113–1188 (2010).
   PubMed Web of Science ®Google Scholar
• O‘Connor AB , DworkinRH. Treatment of neuropathic pain: an overview of recent guidelines. Am. J. Med.122(Suppl. 10) , S22–S32 (2009).
   PubMed Web of Science ®Google Scholar
• The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch. Intern. Med.151(11) , 2225–2229 (1991).
   PubMedGoogle Scholar
• Stillman M . Clinical approach to patients with neuropathic pain. Cleve. Clin. J. Med.73(8) , 726–739 (2006).
   PubMed Web of Science ®Google Scholar
• Backonja MM , IrvingG, ArgoffC. Rational multidrug therapy in the treatment of neuropathic pain. Curr. Pain Headache Rep.10(1) , 34–38 (2006).
   PubMedGoogle Scholar
• Backonja MM , MalanTP, VanhoveGF, TobiasJK. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med.11(4) , 600–608 (2010).
   PubMed Web of Science ®Google Scholar
• Simpson DM , BrownS, TobiasJ. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology70(24) , 2305–2313 (2008).
   PubMed Web of Science ®Google Scholar
• Irving GA , BackonjaMM, DuntemanE et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 12(1) , 99–109 (2011).
   PubMed Web of Science ®Google Scholar
• Backonja M , WallaceMS, BlonskyER et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 7(12) , 1106–1112 (2008).
   PubMed Web of Science ®Google Scholar
• McCormack PL . Capsaicin dermal patch: in non-diabetic peripheral neuropathic pain. Drugs70(14) , 1831–1842 (2010).
   PubMed Web of Science ®Google Scholar
• Premkumar LS , SikandP. TRPV1: a target for next generation analgesics. Curr. Neuropharmacol.6(2) , 151–163 (2008).
   PubMed Web of Science ®Google Scholar
• Wallace M , PappagalloM. Qutenza®: a capsaicin 8% patch for the management of postherpetic neuralgia. Expert Rev. Neurother.11(1) , 15–27 (2011).
   PubMed Web of Science ®Google Scholar
• Anand P , BleyK. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br. J. Anaesth.107(4) , 490–502 (2011).
   PubMed Web of Science ®Google Scholar
• England J , WagnerT, KernKU, Roth-DaniekA, SellA. The capsaicin 8% patch for peripheral neuropathic pain. Br. J. Nurs.20(15) , 926–931 (2011).
   PubMedGoogle Scholar
• Hjermstad MJ , FayersPM, HaugenDF et al. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: a systematic literature review. J. Pain Symptom Manage. 41(6) , 1073–1093 (2011).
   PubMed Web of Science ®Google Scholar
• Baron R , TolleTR. Assessment and diagnosis of neuropathic pain. Curr. Opin Support Palliat. Care2(1) , 1–8 (2008).
   PubMedGoogle Scholar
• Baron R , BinderA, WasnerG. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol.9(8) , 807–819 (2010).
   PubMed Web of Science ®Google Scholar
• Lam VY , WallaceM, SchulteisG. Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. J. Pain12(3) , 323–330 (2011).
   PubMed Web of Science ®Google Scholar
• Craft RM , PorrecaF. Tetracaine attenuates irritancy without attenuating desensitization produced by intravesical resiniferatoxin in the rat. Pain57(3) , 351–359 (1994).
   PubMed Web of Science ®Google Scholar
• Kern KU , PooleC, NowackW. Treatment of neuropathic pain with the capsaicin 8% patch (QUTENZA™): is pre-treatment with lidocaine necessary? Presented at: Pain in Europe VII: 17th Congress of the European Federation of IASP® CHAPTERS (EFIC). Hamburg, Germany, 21–24 September 2011.
   Google Scholar
• Wagner T , PooleC, Roth-DaniekA. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Presented at: 15th Congress of the European Federation of Neurological Societies (EFNS). Budapest, Hungary, 10–13 September 2011.
   Google Scholar
• Simpson DM , GazdaS, BrownS et al. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J. Pain Symptom Manage. 39(6) , 1053–1064 (2010).
   PubMed Web of Science ®Google Scholar
• Papoiu AD , YosipovitchG. Topical capsaicin. The fire of a ‘hot‘ medicine is reignited. Expert Opin Pharmacother.11(8) , 1359–1371 (2010).
   PubMed Web of Science ®Google Scholar
• Zegarska B , LelinskaA, TyrakowskiT. Clinical and experimental aspects of cutaneous neurogenic inflammation. Pharmacol. Rep.58(1) , 13–21 (2006).
   PubMed Web of Science ®Google Scholar
• Carpenter SE , LynnB. Vascular and sensory responses of human skin to mild injury after topical treatment with capsaicin. Br. J. Pharmacol.73(3) , 755–758 (1981).
   PubMed Web of Science ®Google Scholar
• Lynn B , YeW, CotsellB. The actions of capsaicin applied topically to the skin of the rat on C-fibre afferents, antidromic vasodilatation and substance P levels. Br. J. Pharmacol.107(2) , 400–406 (1992).
   PubMed Web of Science ®Google Scholar
• Peppin JF , MajorsK, WebsterLR, TobiasJK, VanhoveGF. Tolerability of NGX-410, a capsaicin 8% patch for peripheral neuropathic pain. J. Pain Res.4 , 385–392 (2011).
   PubMedGoogle Scholar
• Wagner T , PooleC, Roth-DaniekA. Reduction in concomitant neuropathic pain (NP) medication use after treatment with the capsaicin 8% patch: a retrospective analysis. Presented at: Pain in Europe VII: 17th Congress of the European Federation of IASP® CHAPTERS (EFIC). Hamburg, Germany, 21–24 September 2011.
   Google Scholar
• Kennedy WR , VanhoveGF, LuSP et al. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J. Pain 11(6) , 579–587 (2010).
   PubMed Web of Science ®Google Scholar
• Kern KU , NowackW. Is wind-down of neuropathic pain possible with repeated capsaicin 8% patch (QUTENZA™) treatments? Presented at: Pain in Europe VII: 17th Congress of the European Federation of IASP CHAPTERS (EFIC). Hamburg, Germany, 21–24 September 2011.
   Google Scholar
• Dickenson AH . Spinal cord pharmacology of pain. Br. J. Anaesth.75(2) , 193–200 (1995).
   PubMed Web of Science ®Google Scholar
• Eide PK . Wind-up and the NMDA receptor complex from a clinical perspective. Eur. J. Pain4(1) , 5–15 (2000).
   PubMed Web of Science ®Google Scholar
• Clifford D , SimpsonD, BrownS et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J. Acquir. Immune Defic. Syndr. 59(2) , 126–133 (2012).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Astellas Pharma Europe Ltd. Summary of product characteristics: Qutenza 179 mg cutaneous patch. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000909/WC500040453.pdf (Accessed 4October2011)
   Google Scholar
• AstraZeneca UK Ltd. Summary of product characteristics: EMLA cream 5%. www.medicines.org.uk/EMC/medicine/171/SPC/EMLA+Cream+5/ (Accessed 11April2012)
   Google Scholar
• Medicines and healthcare product regulatory agency (MHRA). LMX 4 lidocaine 4% w/w cream: PL 20685/0034 (2007). www.mhra.gov.uk/home/groups/l-unit1/documents/websiteresources/con2033763.pdf (Accessed 4October2011)
   Google Scholar
• Method of pre-treatment for application of QUTENZA capsaicin 8% patch (LIFT). www.clinicaltrials.gov/ct2/show/NCT01416116?term=NCT01416116&rank=1 (Accessed 13November2011)
   Google Scholar
• Woolf CJ. Pain hypersensitivity (2009). www.wellcome.ac.uk/en/pain/microsite/science4.html (Accessed 19January2012)
   Google Scholar
• Safety and effectiveness of repeated administration of QUTENZA patches for treatment of pain caused by nerve damage (STRIDE) (2011). http://clinicaltrials.gov/ct2/show/NCT01252160?term=01252160&rank=1 (Accessed 17January2012)
   Google Scholar